The Technical Analyst
Select Language :
Kalvista Pharmaceuticals [KALV]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Kalvista Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: BUY (auto-tracking)

Kalvista Pharmaceuticals is listed at the  Exchange

7.14% $11.86

America/New_York / 28 mar 2024 @ 16:00


Kalvista Pharmaceuticals: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 500.35 mill
EPS: -3.12
P/E: -3.80
Earnings Date: Mar 10, 2024
SharesOutstanding: 42.19 mill
Avg Daily Volume: 0.784 mill
RATING 2024-03-28
B-
Neutral
RATINGS
Rating CashFlow: Neutral
Return On Equity: Strong Sell
Return On Asset: Sell
DE: Neutral
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
4/221/232/233/234/231/24
Revenuen/an/an/an/an/an/a
Gr.Profitn/a
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -3.80 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.65x
Company: PE -3.80 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$1.721
(-85.49%) $-10.14
Date: 2024-03-29
Expected Trading Range (DAY)

$ 10.92 - 12.80

( +/- 7.89%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-03-06 Palleiko Benjamin L Buy 250 000 Restricted Stock Unit
2024-02-20 Venrock Healthcare Capital Partners Iii, L.p. Buy 655 738 Pre-Funded Warrants (Right to Buy)
2024-02-17 Feener Edward P. Buy 18 788 Common Stock
2024-02-20 Feener Edward P. Sell 8 397 Common Stock
2024-02-20 Feener Edward P. Sell 19 591 Common Stock
INSIDER POWER
65.05
Last 99 transactions
Buy: 3 039 025 | Sell: 648 624

Forecast: 16:00 - $11.83

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $11.83
Forecast 2: 16:00 - $11.83
Forecast 3: 16:00 - $11.83
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $11.86 (7.14% )
Volume 2.15 mill
Avg. Vol. 0.784 mill
% of Avg. Vol 274.62 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Kalvista Pharmaceuticals Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Kalvista Pharmaceuticals Inc

RSI

Intraday RSI14 chart for Kalvista Pharmaceuticals Inc

Last 10 Buy & Sell Signals For KALV

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:35sell$14.73N/AActive
Profile picture for
            Kalvista Pharmaceuticals Inc

KALV

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Last 10 Buy Signals

Date Signal @
XAUTUSDMar 29 - 07:19$2 232.78
POLYXUSDMar 29 - 07:190.529
VRXUSDMar 29 - 07:1862.71
TOMOUSDMar 29 - 07:13$1.061
POOLXUSDMar 29 - 07:095.22
COREUSDMar 29 - 07:086 994.98
PENDLEUSDMar 29 - 07:094.21
BFICUSDMar 29 - 07:079.89
RETH2USDMar 29 - 06:593 540.59
PUNDIXUSDMar 29 - 06:580.696

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.